An observational study in Extrapyramidal Symptoms, Drug-induced Parkinsonism and Akathisia, Drug-Induced, sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Shanghai Mental Health Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Tardive Dyskinesia with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Tardive Dyskinesia · China.
Among the 10 studies in Tardive Dyskinesia with a site in China, this one is the only one that started in 2026, is the only observational one, and was the 10th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →3 of the 10 studies in Tardive Dyskinesia with a site in China are open now. Recruiting first, the newest first:
Peking University Sixth Hospital · Sites in China
Ages 18–65
Luye Pharma Group Ltd. · Sites in China
Ages 18–64
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 1
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 64 across the 9 interventional studies, 180 across the 1 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 5 most frequent:
Shanghai Mental Health Center is the lead sponsor of 277 studies on the registry; 95 are open to participants now.
Shanghai Mental Health Center has 2 studies filed under Tardive Dyskinesia — fewer than ten, so there is no comparison to draw.
1 of the studies in Tardive Dyskinesia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07715994Shanghai Mental Health CenterA Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Tardive Dyskinesia with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective, single-center observational study aims to develop and validate a computer-assisted tool for the objective quantitative assessment of extrapyramidal symptoms (EPS).
The study will enroll 180 participants, including 90 healthy controls and 90 participants with clinically confirmed antipsychotic-induced EPS. The healthy control group will provide reference data on normal movement, while the EPS disease group will provide data on abnormal movements associated with drug-induced parkinsonism, akathisia, or tardive dyskinesia.
Each participant will complete one study visit lasting approximately 60 minutes. During the visit, a trained psychiatrist will assess EPS using the Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS). Participants will also complete standardized movement tasks while a non-contact computer vision system records and analyzes movement features. The device-based assessment will be repeated after a short rest to evaluate the stability of the measurements.
Data collected earlier in the study will be used to develop and optimize the assessment tool. After the algorithm is finalized and locked, data from subsequently enrolled participants will be used for independent validation. The study will evaluate how closely the tool's results agree with clinician assessments, as well as its ability to identify EPS, produce stable repeated measurements, and operate feasibly and safely in a clinical setting.
This is an observational study. The study does not assign treatment, change participants' medications, or use the investigational tool to make treatment decisions.
This is a prospective, single-center, two-cohort observational study designed to develop and validate an objective quantitative assessment and computer-assisted diagnostic tool for extrapyramidal symptoms (EPS). The study focuses on EPS associated with antipsychotic treatment, including drug-induced parkinsonism, akathisia, and tardive dyskinesia.The observational study model is classified as Other because this is a two-cohort diagnostic accuracy and tool development and validation study with a single study visit, rather than a conventional longitudinal cohort study.
A total of 180 evaluable participants are planned for enrollment. The study includes two cohorts: 90 healthy controls and 90 participants with clinically confirmed antipsychotic-induced EPS. The healthy control cohort will provide reference data for normal physiological movement and will help establish a baseline for distinguishing normal movement variability from abnormal movement features. The EPS disease cohort will provide positive reference data representing clinically confirmed abnormal movement patterns and different levels of symptom severity. The two cohorts are used as reference populations for tool development and validation and are not treatment comparison groups.
Each participant will complete a single study visit lasting approximately 60 minutes. After written informed consent, demographic and relevant clinical information will be collected. For participants in the EPS disease cohort, information on psychiatric history, antipsychotic treatment, time of the most recent medication dose, and use of medications for EPS will also be recorded.
A trained senior psychiatrist will then conduct standardized clinical EPS assessments using the Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS). The clinical assessment includes observation of posture and spontaneous movement, examination of orofacial movements, standardized upper-limb and hand movements, standing and walking tasks, and assessment of subjective symptoms when applicable. Clinician ratings will be recorded separately from the device assessment, and device operators will not have access to the clinician ratings during data collection.
Participants will subsequently complete a standardized device-based assessment using a non-contact image-based computer vision system. The assessment tasks are designed as a digital representation of movement features examined during routine clinical EPS assessment. Tasks include standardized periods of sitting, upper-limb positioning and movement, orofacial movements such as mouth opening and tongue protrusion, hand and finger movements, standing, walking, and turning. The system extracts facial, hand, and body keypoint information and derives quantitative movement and kinematic features.
After the first device-based assessment, participants will have a short rest of approximately 5 minutes. When physically able and willing to continue, they will complete a second assessment using the same device, instructions, and task sequence. The repeated assessment will be used to evaluate the stability and repeatability of the device-based measurements.
The study uses a two-stage development and validation design. Approximately the first 70% of evaluable participants, including participants from both cohorts, will contribute data to the tool development stage. Device-derived movement features will be aligned with clinician-rated SAS, BARS, and AIMS results to support model training, parameter optimization, and development of objective severity grading. After the predefined development process is completed, the algorithm will be locked and no further model modification will be made for the validation analysis.
Approximately the final 30% of evaluable participants enrolled after algorithm lock will form an independent validation set. The locked system will be evaluated on these previously unseen data. The validation stage will assess agreement between device-based and clinician-rated EPS severity grading, the ability of the tool to distinguish participants with clinically confirmed EPS from healthy controls, the stability of repeated measurements, and the feasibility and safety of the standardized assessment procedure.
This is a non-interventional observational study. Participants are not assigned to treatments or medications by the study protocol. The study does not require discontinuation, dose reduction, dose escalation, or substitution of antipsychotic or anti-EPS medications. Outputs from the investigational system will be used for research purposes and will not be used to make immediate clinical treatment decisions.
The study population will consist of a Control Group and an EPS Disease Group recruited at Shanghai Mental Health Center. Potential participants in the EPS Disease Group will be identified and screened by research physicians in relevant outpatient clinics, inpatient wards, and other institutionally approved recruitment settings. Participants in the Control Group may be recruited through institutionally approved notices or by study researchers. Eligibility will be confirmed according to the predefined inclusion and exclusion criteria. A total of 180 evaluable participants are planned, including 90 participants in the Control Group and 90 participants in the EPS Disease Group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A. Control Group
B. EPS Disease Group
Clinically confirmed antipsychotic-induced extrapyramidal symptoms meeting at least one of the following criteria:
Exclusion Criteria
The following exclusion criteria apply to both groups:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants without current or past psychiatric disorders and without extrapyramidal symptoms associated with antipsychotic treatment. Participants will undergo standardized clinical scale assessments and two repeated device-based movement assessments during a single study visit. Data from this group will provide reference information on normal movement characteristics for development and validation of the objective quantitative assessment and computer-assisted diagnostic tool.
Diagnostic Test: Computer-Assisted Objective Assessment of Extrapyramidal Symptoms
Participants with schizophrenia or related psychotic disorders who have received regular antipsychotic treatment and have clinically confirmed antipsychotic-induced extrapyramidal symptoms. Eligible symptoms include drug-induced parkinsonism, akathisia, and/or tardive dyskinesia according to predefined clinical criteria. Participants will undergo standardized clinical scale assessments and two repeated device-based movement assessments during a single study visit. Data from this group will be used for development and validation of the objective quantitative assessment and computer-assisted diagnostic tool.
Diagnostic Test: Computer-Assisted Objective Assessment of Extrapyramidal Symptoms
Participants will complete a standardized, non-contact, image-based computer-assisted assessment of extrapyramidal symptoms. The assessment consists of predefined sitting, orofacial, hand and finger, upper-limb, standing, walking, and turning tasks. The system processes image data to extract facial, hand, and body keypoints and derive quantitative movement and kinematic features. Each participant will complete the same assessment twice during a single study visit, separated by approximately 5 minutes, to evaluate test-retest reliability. The assessment is conducted for research purposes only. It does not assign or modify treatment, and its outputs will not be used to make immediate clinical treatment decisions.
Maximum Weighted Kappa Coefficient Across Three EPS Subtype-Specific Device-Clinical Severity Classification Comparisons
The primary outcome is a single aggregated agreement metric defined as the maximum weighted kappa coefficient among three prespecified subtype-specific comparisons. Weighted kappa coefficients with 95% confidence intervals will be calculated separately for: (1) device-side drug-induced parkinsonism severity classification versus Simpson-Angus Scale (SAS)-based classification; (2) device-side akathisia severity classification versus Barnes Akathisia Rating Scale (BARS)-based classification; and (3) device-side tardive dyskinesia severity classification versus Abnormal Involuntary Movement Scale (AIMS)-based classification. The maximum of the three weighted kappa coefficients will be reported as the primary outcome in the independent test set after algorithm locking. The prespecified primary success criterion will be met if at least one of the three subtype-specific weighted kappa coefficients reaches or exceeds the predefined agreement threshold.
Time frame: Single study visit, Day 1
Test-Retest Reliability of Device-Side Repeated Acquisition Results
Participants will complete two identical standardized device-side motion acquisitions during the same study visit. The intraclass correlation coefficient (ICC) will be calculated for continuous motion features generated by the two acquisitions. Weighted kappa will be calculated for predicted classification results to evaluate short-term stability.
Time frame: Two assessments during the single study visit, separated by approximately 5 minutes, Day 1
Sensitivity of the Device-Side System for Identifying EPS
Using the prespecified SAS-, BARS-, and AIMS-based clinical criteria as the reference standard, sensitivity will be calculated as true positives divided by true positives plus false negatives, multiplied by 100, with a 95% confidence interval. Analysis will use the independent test set after algorithm locking.
Time frame: Single study visit, Day 1
Specificity of the Device-Side System for Identifying EPS
Using the prespecified SAS-, BARS-, and AIMS-based clinical criteria as the reference standard, specificity will be calculated as true negatives divided by true negatives plus false positives, multiplied by 100, with a 95% confidence interval. Analysis will use the independent test set after algorithm locking.
Time frame: Single study visit, Day 1
Accuracy of the Device-Side System for Identifying EPS
Using the prespecified clinical reference standard, accuracy will be calculated as true positives plus true negatives divided by the total number of evaluated participants, multiplied by 100, with a 95% confidence interval. Analysis will use the independent test set after algorithm locking.
Time frame: Single study visit, Day 1
Positive Predictive Value of the Device-Side System for Identifying EPS
Positive predictive value will be calculated as true positives divided by true positives plus false positives, multiplied by 100, with a 95% confidence interval. Analysis will use the independent test set after algorithm locking.
Time frame: Single study visit, Day 1
Negative Predictive Value of the Device-Side System for Identifying EPS
Negative predictive value will be calculated as true negatives divided by true negatives plus false negatives, multiplied by 100, with a 95% confidence interval. Analysis will use the independent test set after algorithm locking.
Time frame: Single study visit, Day 1
Area Under the Receiver Operating Characteristic Curve for the Device-Side System in Identifying EPS
A receiver operating characteristic curve will be generated using a continuous output produced by the locked device-side system and the binary clinical reference classification. The area under the curve will be calculated with a 95% confidence interval in the independent test set after algorithm locking. Higher values indicate better discrimination.
Time frame: Single study visit, Day 1
Number of Participants With One or More Adverse Events During Study Procedures
The number of participants experiencing at least one adverse event during the study visit will be recorded. Potential events include falls, gait instability, muscle fatigue or soreness, anxiety, fear, agitation, refusal to undergo testing, and transient fluctuation of psychiatric symptoms. Severity, management, outcome, and relationship to study procedures will be summarized descriptively.
Time frame: Throughout the single study visit, approximately 60 minutes, Day 1
Plan to share: No — Individual participant data will not be shared with other researchers because the study involves potentially identifiable facial and body movement data from psychiatric participants. Original images and key frame images will not be publicly shared or transferred outside the study institution. No external individual-level data sharing mechanism is currently planned.
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Apr 2027, 9 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Mental Health Center →